Day: March 29, 2025

NEWPORT BEACH, Calif., March 29, 2025 (GLOBE NEWSWIRE) — GivBux, Inc. (OTC: GBUX) (“GivBux” or the Company”), a publicly traded Super App and charitable giving platform, today announced the intended sale of a 30% equity stake in the Company for $212 million. The transaction is designed to be completed through a non-dilutive structure to protect and enhance long-term shareholder value. As part of the transaction, $212 million will be invested into an income-oriented strategy managed by an experienced, real estate focused private credit asset manager. This multiyear commitment is designed to produce consistent cash flow to provide funding to GivBux to support the overall expansion of the Company and its Super App platform. The majority shareholder of GivBux has voluntarily agreed to retire a portion of its shares...

NEWPORT NEWS, Va., March 29, 2025 (GLOBE NEWSWIRE) — HII (NYSE: HII) hosted commencement exercises today, celebrating 77 graduates of the company’s Newport News Shipbuilding Apprentice School. The ceremony was held at Liberty Live Church in Hampton. Virginia State Sen. Louise Lucas delivered the keynote commencement address. “The technical skills you acquired here will serve as a foundation upon which you build your career,” Lucas told the graduates. “The leadership lessons learned in The Apprentice School and in the shipyard will open doors to roads you might not have ever imagined.” NNS President Kari Wilkinson addressed the graduates as the shipyard’s newest leaders. “You have each signed up for an incredible, important mission,” Wilkinson said. “You literally build freedom for our nation, and I’m proud to stand beside...

– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile – – Lorundrostat is a highly selective aldosterone synthase inhibitor that disrupts aldosterone biosynthesis rather than blocking the mineralocorticoid receptor – – Data from Advance-HTN support the potential of lorundrostat as a best-in-class treatment for high-risk patients with uncontrolled or resistant hypertension who would normally be treated in a specialist setting – RADNOR, Pa., March 29, 2025 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases...

Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial1. Data were presented at the American College of Cardiology’s (ACC) Annual Scientific Session and Expo in Chicago, US, while simultaneously published today in New England Journal of Medicine2. Rybelsus®, the only approved oral GLP-1 medicine, demonstrated this risk reduction on top of standards of cardiovascular and diabetes care. Based on SOUL findings, Novo Nordisk submitted a label extension application for Rybelsus® for CV event risk reduction to the US FDA and EMA.Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral semaglutide)...

Ozempic® improved maximum walking distance by 13% vs placebo in adults with type 2 diabetes and peripheral artery disease (PAD) in the phase 3 STRIDE trial1. Data were presented at the American College of Cardiology’s (ACC) Annual Scientific Session and Expo in Chicago, US, while simultaneously published today in The Lancet2. Approximately 230 million people globally have PAD, a severe form of atherosclerotic cardiovascular disease3, and nearly one in three people with PAD have type 2 diabetes4.Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic® (semaglutide 1.0 mg) in adults with type 2 diabetes and PAD, at the American College of Cardiology’s (ACC) Annual Scientific...